Sjoerd Wadman
Directeur Technique/Scientifique/R&D chez LanthioPep BV
Profil
Dr. Sjoerd Wadman is Vice President-Research & Development at LanthioPep BV and Vice President-Research & Development at Lanthio Pharma BV.
Dr. Wadman was previously employed as a Director-Therapeutic Projects by Novacta Biosystems Ltd., Project & Group Leader by Morphochem AG, and Project Leader by GlaxoSmithKline Plc.
He received his undergraduate degree from The University of Manchester and a doctorate degree from The University of Southampton.
Postes actifs de Sjoerd Wadman
| Sociétés | Poste | Début |
|---|---|---|
LanthioPep BV
 LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Sjoerd Wadman
| Sociétés | Poste | Fin |
|---|---|---|
Novacta Biosystems Ltd.
 Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/12/2011 |
Morphochem AG
 Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Corporate Officer/Principal | 01/01/2004 |
| GSK PLC | Corporate Officer/Principal | 01/12/2000 |
Lanthio Pharma BV
 Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Directeur Technique/Scientifique/R&D | - |
Formation de Sjoerd Wadman
| The University of Southampton | Doctorate Degree |
| The University of Manchester | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
LanthioPep BV
LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Health Technology |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
Novacta Biosystems Ltd.
Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Health Technology |
Morphochem AG
Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Commercial Services |
